Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 3, 2015, Pages 664-675

  Cutrera, Jeffry ^a   King, Glenn ^b   Jones, Pamela ^b   Kicenuik, Kristin ^b   Gumpel, Elias ^b   Xia, Xueqing ^a   Li, Shulin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b GULF COAST VETERINARY SPECIALISTS   (United States)

Author keywords

Cancer; Chemotherapy; Electroporation; Immunotherapy; Interleukin 12; Personalized therapy

Indexed keywords

ANIMALIA;

ANTINEOPLASTIC AGENT; BLEOMYCIN; DEOXYCYTIDINE; GEMCITABINE; INTERLEUKIN 12;

ANALOGS AND DERIVATIVES; ANIMAL; DOG; ELECTROPORATION; FEMALE; GENE THERAPY; GENETICS; IMMUNOLOGY; MALE; NEOPLASMS; PLASMID; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLEOMYCIN; DEOXYCYTIDINE; DOGS; ELECTROPORATION; FEMALE; GENETIC THERAPY; INTERLEUKIN-12; MALE; NEOPLASMS; PLASMIDS; TREATMENT OUTCOME;

EID: 84923441243     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12382     Document Type: Article

References (50)

1. Cutrera J, Torrero M, Shiomitsu K, et al. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. In: Li S, editor. Electroporation protocols: preclinical and clinical gene medicine. New Jersey: Humana Press; 2008. pp. 319-25.
2. Kishida T, Asada H, Itokawa Y, et al. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther. 2003; 8: 738-45.
3. Reed SD, Fulmer A, Buckholz J, et al. Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther. 2010; 17: 457-64.
4. Adelstein DJ. Systemic chemotherapy for squamous cell head and neck cancer. Exp Opin Pharmacother. 2003; 4: 2151-63.
5. DeConti RC. Chemotherapy of squamous cell carcinoma of the skin. Semin Oncol. 2012; 39: 145-9.
6. Chuang TF, Lee SC, Liao KW, et al. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. Int J Cancer. 2009; 125: 698-707.
7. Cohen J. IL-12 deaths: explanation and a puzzle. Science. 1995; 270: 908.
8. Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol. 2009; 16: 191-9.
9. Kodre V, Cemazar M, Pecar J, et al. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. In Vivo. 2009; 23: 55-62.
10. Spugnini EP, Dotsinsky I, Mudrov N, et al. Successful rescue of an apocrine gland carcinoma metastatic to the cervical lymph nodes by mitoxantrone coupled with trains of permeabilizing electrical pulses (electrochemotherapy). In Vivo. 2008; 22: 51-3.
11. Spugnini EP, Filipponi M, Romani L, et al. Local control and distant metastasis after electrochemotherapy of a canine anal melanoma. In Vivo. 2007; 21: 897-9.
12. Tozon N, Kodre V, Sersa G, et al. Effective treatment of perianal tumors in dogs with electrochemotherapy. Anticancer Res. 2005; 25: 839-45.
13. Spugnini EP, Vincenzi B, Citro G, et al. Evaluation of cisplatin as an electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in dogs. J Vet Intern Med. 2011; 25: 407-11.
14. Miklavcic D, Sersa G, Brecelj E, et al. Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med Biol Eng Comput. 2012; 50: 1213-25.
15. Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008; 26: 5896-903.
16. Torrero MN, Henk WG, Li S. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res. 2006; 12: 257-63.
17. Pavlin D, Cemazar M, Sersa G, et al. IL-12 based gene therapy in veterinary medicine. J Transl Med. 2012; 10: 234.
18. Buttner M, Belke-Louis G, Rziha HJ, et al. Detection, cDNA cloning and sequencing of canine interleukin 12. Cytokine. 1998; 10: 241-8.
19. Okano F, Satoh M, Yamada K. Cloning and expression of the cDNA for canine interleukin-12. J Interferon Cytokine Res. 1997; 17: 713-8.
20. Cutrera J, King G, Jones P, et al. Managing local swelling following intratumoral electro-chemo-gene therapy. In: Li S, Cutrera J, Heller R, Teissie J, editors. Electroporation protocols: preclinical and clinical gene medicine. 2nd ed. New Jersey: Humana; 2014. pp. 233-9.
21. Cutrera J, Dibra D, Xia X, et al. Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy. Mol Ther. 2011; 19: 1468-77.
22. Li S, Zhang L, Torrero M, et al. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol Ther. 2005; 12: 942-9.
23. Escoffre JM, Rols MP. Electrochemotherapy: progress and prospects. Curr Pharm Des. 2012; 18: 3406-15.
24. Mir LM. Bases and rationale of the electrochemotherapy. EJC Suppl. 2006; 4: 38-44.
25. Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012; 2: 260-9.
26. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997; 3: 409-17.
27. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res. 2007; 13: 4677-85.
28. Cutrera J, Li S. Passive and active tumor homing cytokine therapy. In: Lustgarten J, Cui Y, Li S, editors. Targeted cancer immune therapy. New York: Springer; 2009. pp. 97-113.
29. Wei LZ, Xu Y, Nelles EM, et al. Localized interleukin-12 delivery for immunotherapy of solid tumours. J Cell Mol Med. 2013; 17: 1465-74.
30. Li S, Cutrera J, Teissie J, Heller R. Electroporation protocols: preclinical and clinical gene medicine. 2nd ed. New Jersey: Humana Press; 2014.
31. Teissie J. Electropermeabilization of the cell membrane. In: Li S, Cutrera J, Heller R, Teissie J, editors. Electroporation protocols: preclinical and clinical gene medicine. 2nd ed. New Jersey: Humana; 2014. pp. 25-46.
32. Heller L, Merkler K, Westover J, et al. Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. Clin Cancer Res. 2006; 12: 3177-83.
33. Spugnini EP, Dotsinsky I, Mudrov N, et al. Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma. J Exp Clin Cancer Res. 2008; 27: 58.
34. Au JT, Mittra A, Song TJ, et al. Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response. Surgery. 2013; 154: 496-503.
35. Neal R, Rossmeisl J, Garcia P, et al. Successful treatment of a large soft tissue sarcoma with irreversible electroporation. J Clin Oncol. 2011; 29: e372-7.
36. Motzer RJ, Rakhit A, Schwartz LH, et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res. 1998; 4: 1183-91.
37. Gautam SC, Xu YX, Dumaguin M, et al. Interleukin-12 (IL-12) gene therapy of leukemia: immune and anti-leukemic effects of IL-12-transduced hematopoietic progenitor cells. Cancer Gene Ther. 2000; 7: 1060-8.
38. Heinzerling LM, Feige K, Rieder S, et al. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med. 2001; 78: 692-702.
39. Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther. 2002; 9: 64-74.
40. Muller J, Feige K, Wunderlin P, et al. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother. 2011; 34: 58-64.
41. Muller JM, Wissemann J, Meli ML, et al. In vivo induction of interferon gamma expression in grey horses with metastatic melanoma resulting from direct injection of plasmid DNA coding for equine interleukin 12. Schweiz Arch Tierheilkd. 2011; 153: 509-13.
42. Pavlin D, Cemazar M, Cor A, et al. Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol. 2011; 45: 31-9.
43. Li S. Electroporation protocols: preclinical and clinical gene medicine. New Jersey: Humana Press; 2008.
44. Tozon N, Sersa G, Cemazar M. Electrochemotherapy: potentiation of local antitumour effectiveness of cisplatin in dogs and cats. Anticancer Res. 2001; 21: 2483-8.
45. Spugnini EP, Baldi A. Electrochemotherapy in veterinary oncology: from rescue to first line therapy. Methods Mol Biol. 2014; 1121: 247-56.
46. Mali B, Miklavcic D, Campana L, et al. Tumor size and effectiveness of electrochemotherapy. Radiol Oncol. 2013; 47: 32-41.
47. Sedlar A, Kranjc S, Dolinsek T, et al. Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma. BMC cancer. 2013; 13: 38.
48. Sedlar A, Dolinsek T, Markelc B, et al. Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol. 2012; 46: 302-11.
49. Vanherberghen M, Day MJ, Delvaux F, et al. An immunohistochemical study of the inflammatory infiltrate associated with nasal carcinoma in dogs and cats. J Comp Pathol. 2009; 141: 17-26.
50. Quetglas JI, Hervas-Stubbs S, Smerdou C. The immunological profile of tumor-bearing animals determines the outcome of cancer immunotherapy. Oncoimmunology. 2013; 2: e24499-3. Doi: 10.4161/onci.24499.